| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/27/2005 | EP1526183A2 Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei |
| 04/27/2005 | EP1526178A1 MSP-3-like family of genes |
| 04/27/2005 | EP1526175A2 Coronavirus, nucleic acid, protein and methods for the generation of vaccine, medicaments and diagnostics |
| 04/27/2005 | EP1526172A1 Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
| 04/27/2005 | EP1526141A2 MHC complexes and uses thereof |
| 04/27/2005 | EP1525313A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemaggllutinin/esterase |
| 04/27/2005 | EP1525312A2 Brachyspira hyodysenteriae vaccine |
| 04/27/2005 | EP1525307A2 Modified adamts4 molecules and method of use thereof |
| 04/27/2005 | EP1524995A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 04/27/2005 | EP1524994A1 Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 04/27/2005 | EP1524993A2 Neisserial vaccine compositions comprising a combination of antigens |
| 04/27/2005 | EP1524992A2 Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis |
| 04/27/2005 | EP1524991A1 Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
| 04/27/2005 | EP1524990A2 Vaccine composition comprising lipooligosaccharide with reduced phase variability |
| 04/27/2005 | EP1253932B1 Botulinum toxin pharmaceutical compositions |
| 04/27/2005 | EP1150713B1 Vaccine formulation comprising monoglycerides or fatty acids as adjuvant |
| 04/27/2005 | EP1150707B1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
| 04/27/2005 | EP1135153B1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 04/27/2005 | EP1039931B1 Multivalent recombinant antibodies for treating hrv infections |
| 04/27/2005 | EP0939818B1 Recombinant toxin fragments |
| 04/27/2005 | EP0935470B1 Method for treating allergic lung disease |
| 04/27/2005 | EP0743983B1 Mammalian thymokine genes |
| 04/27/2005 | CN1610748A Recombinant MVA capable of expressing structural HCV antigens |
| 04/27/2005 | CN1610743A Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/27/2005 | CN1610697A E type hepatitis virus monoclonal antibody or its conjugated active fragment and use thereof |
| 04/27/2005 | CN1610696A Antibodies that immunospecifically bind to TRAIL receptors |
| 04/27/2005 | CN1610695A Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 04/27/2005 | CN1610560A Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| 04/27/2005 | CN1610556A Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 04/27/2005 | CN1609617A Composition and method for diagnosing and preventing serious acute respiratory syndrome(SARS) |
| 04/27/2005 | CN1609616A Specific markers for diabetes |
| 04/27/2005 | CN1609213A Gene cloning of polyepitope antigen of hepatitis C virus and its coding sequence |
| 04/27/2005 | CN1609204A Bivalent hepatitis B-encephalitis B vaccine |
| 04/27/2005 | CN1609203A Human ovary carcinoma resisting monoclonal antibody hybridoma cell line and its monoclonal antibody and application |
| 04/27/2005 | CN1609197A High-yield reverse immunization for finding tumor specific antigen and tumor specific antigen determinant |
| 04/27/2005 | CN1609196A High-yield T lymphocyte cloning technology for finding tumor specific antigen and tumor specific antigen determinant |
| 04/27/2005 | CN1609123A Variable region sequence of hepatitis B virus monoclonal antibody, gene engineering antibody containing the variable region and its use |
| 04/27/2005 | CN1609118A Cell wall acyl-alanyl-D-isoglutamine derivative and its prepn, medicine composition and use |
| 04/27/2005 | CN1608673A Prepn process of S190 polypeptide vaccine and its application in resisting SARS virus |
| 04/27/2005 | CN1198933C Epitopes of protein pre-M/M of dengue virus, synthetic peptides |
| 04/27/2005 | CN1198932C Streptococcus pneumoniae antigens |
| 04/27/2005 | CN1198931C MOraxella catarrhalis BASB034 polypeptides and uses thereof |
| 04/27/2005 | CN1198927C Vasoactive amine binding molecules |
| 04/27/2005 | CN1198918C Live attenuated bacteria of species actinobacillus pleuropneumoniae |
| 04/27/2005 | CN1198845C Monoclonal antibody inducing programming apoptosis |
| 04/27/2005 | CN1198840C Human papillomavirus 11L1-E7 recombinant protein and its application |
| 04/27/2005 | CN1198665C Method for introducing pharmaceutical drugs and nucleic acid into skeletal muscle |
| 04/27/2005 | CN1198648C High affinity human monoclonal antibodies specific for RSV F-protein |
| 04/27/2005 | CN1198647C Antibodies against human CD40 |
| 04/27/2005 | CN1198646C Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens |
| 04/27/2005 | CN1198642C Pharmaceutical application of mammal cell kinetin synthetic inhibitory factor |
| 04/26/2005 | US6884786 Antitumoral composition based on immunogenic polypeptide with modified cell location |
| 04/26/2005 | US6884785 Compositions and methods for the treatment or prevention of autoimmune diabetes |
| 04/26/2005 | US6884623 Using plant virions for vaccine preparation; gene therapy |
| 04/26/2005 | US6884576 Genetically engineered cell for use in the diagnosis, prevntion and treatment of viral diseases |
| 04/26/2005 | US6884574 Methods of identifying agents which inhibit GPR-9-6 |
| 04/26/2005 | US6884435 A biodegradable polymer of a poly(alpha-hydroxyacid), polyhydroxybutryic acid, polycaprolactone, polyorthoester, polyanhydride or polycyanoacrylate, a cationic detergent and adsorbed polynucleotide antigen; vaccines; injections |
| 04/26/2005 | US6884423 Antimicrobial histone H1 compositions, kits, and methods of use thereof |
| 04/26/2005 | US6884422 Freeze-dried hepatitis A attenuated live vaccine and its stabilizer |
| 04/26/2005 | US6884418 Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| 04/26/2005 | US6884412 Dectection of and methods and composition for prevention and/or treatment of papillomatous digital dermatitis |
| 04/26/2005 | US6884410 Interleukins; for suppressing reactions to alloantigens (graft-versus-host disease/tissue rejection) in organ/bone marrow transplants |
| 04/26/2005 | US6883521 Method and apparatus for dosing single and multi-agent therapy |
| 04/26/2005 | CA2253871C Ret ligand (retl) for stimulating neural and renal growth |
| 04/26/2005 | CA2165954C Prostaglandin receptor fp and dna encoding it |
| 04/26/2005 | CA2123580C Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
| 04/21/2005 | WO2005035779A2 Method |
| 04/21/2005 | WO2005035777A1 Dna vaccines against tumor growth and methods of use thereof |
| 04/21/2005 | WO2005035773A2 Modified cea /b7 vector |
| 04/21/2005 | WO2005035733A2 Modified whole cell, cell extract and omv-based vaccines |
| 04/21/2005 | WO2005035730A2 Dna sequences of the botulinum neurotoxin complex of type a-hall (allergan) strain |
| 04/21/2005 | WO2005035723A2 Tyrosinase mutant and methods of use thereof |
| 04/21/2005 | WO2005035720A2 Methods and use of binding components for improving assay specificity |
| 04/21/2005 | WO2005035714A2 Vaccines for cancer, autoimmune disease and infections |
| 04/21/2005 | WO2005035712A2 Methods and compositions for infectious cdna of sars coronavirus |
| 04/21/2005 | WO2005035588A1 Synthetic polysaccharide antigens for immunological intervention in disease |
| 04/21/2005 | WO2005035584A1 Fully human antibodies against human 4-1bb (cd137) |
| 04/21/2005 | WO2005035583A1 Antibody composition specifically binding to il-5 receptor |
| 04/21/2005 | WO2005035582A1 Composition of antibody capable of specifically binding ccr4 |
| 04/21/2005 | WO2005035581A1 COMPOSITION OF ANTIBODY CAPABLE OF SPECIFICALLY BINDING HUMAN VEGF RECEPTOR Flt-1 |
| 04/21/2005 | WO2005035574A1 IgM HIGH CONCENTRATION STABILIZED SOLUTION |
| 04/21/2005 | WO2005035558A2 Piscirickettsia salmonis antigens and use thereof |
| 04/21/2005 | WO2005035557A2 Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| 04/21/2005 | WO2005035556A2 Sars-coronavirus virus-like particles and methods of use |
| 04/21/2005 | WO2005035555A1 Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies |
| 04/21/2005 | WO2005034996A1 An augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses |
| 04/21/2005 | WO2005034993A1 Vp1 fusion protein vaccin of recombinant foot-and-mouth disease virus |
| 04/21/2005 | WO2005034992A2 Hiv vaccines based on env of multiple clades of hif |
| 04/21/2005 | WO2005034991A1 Improved protocol for enhancing immunization through adoptive transfer of dendritic cells |
| 04/21/2005 | WO2005034983A1 Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders |
| 04/21/2005 | WO2005034979A2 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 04/21/2005 | WO2005034842A2 Peptides useful as hiv fusion inhibitors |
| 04/21/2005 | WO2005034841A2 Anthrax vaccine |
| 04/21/2005 | WO2005034839A2 Porifera-based therapeutic compositions for treating and preventing skin diseases |
| 04/21/2005 | WO2005034733A2 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| 04/21/2005 | WO2005016970A3 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 04/21/2005 | WO2005007876A3 Modulation of interleukin-10 by dhea |
| 04/21/2005 | WO2005004910A3 Hcv vaccines |
| 04/21/2005 | WO2005000891A3 Thrombopoietin proteins with improved properties |
| 04/21/2005 | WO2005000239A3 Lyase treatment for p. carinii |